Peristalsis stimulants: analysis of consumption in different countries of the world
DOI:
https://doi.org/10.24959/uekj.20.2Keywords:
peristalsis stimulants, assortment of drugs, pharmaceutical market, ATC/DDD methodology, consumption of drugsAbstract
Aim. To make an assessment of drugs consumption of the group A03F “Peristalsis stimulants” in Ukraine and some European countries in 2016-2018.
Materials and methods. Data from information system “Pharmexplorer” of Morion company has been used to analyze the assortment and consumption volumes of peristalsis stimulants in Ukraine. Assessment of the volumes, structure and dynamics of drug consumption of this group in Ukraine has been conducted based on the number of consumed defined daily doses (DDD) of drugs using the ATC/DDD methodology and the number of sold drugs packings. The level of investigational drugs consumption at the indicator “DDDs/1000 inhabitants/day” in European countries has been determined by the statistical data of these countries.
Results. The peristalsis stimulants presented in Ukraine in 2016-2018 in the number of 4 international non-patented names, 32-34 trade names, had a fairly wide range of prices for packaging. Their consumption volumes (by the number of sold drugs packings and the number of consumed DDDs) increased in Ukraine from 2016 to 2018. Domperidone had held leading positions in these indicators of consumption. Comparison of peristalsis stimulants consumption level at the indicator “DDDs/1000 inhabitants/day” in 2016-2018 in Ukraine and some European countries (Norway, Lithuania, Latvia and Estonia) determined the highest this group drugs consumption in 2016-2017 in Lithuania, in 2018 – in Ukraine; the smallest volumes of drugs consumption were in Estonia (throughout the study period). Consumption of peristalsis stimulators had increased over the years in Ukraine, in other countries it had decreased. Domperidone was the leader by consumption among peristalsis stimulants in Ukraine, metoclopramide – in the Baltic countries and Norway.
Conclusions. Peristaltic stimulants consumption by the number of sold drugs packings and by the number of consumed DDD increased from 2016 to 2018 in Ukraine. Ukraine differed from the studied European countries in terms of volume, structure and dynamics of this group drugs consumption at the indicator “DDDs/1000 inhabitants/day” in 2016-2018.
References
Minushkin, O. N., Maslovsky, L. V., & Anikina, N. Y. (2016). Disturbances of motility of gastrointestinal tract in practice of therapist and some therapeutic approaches. Medical Council, (14), 36–41. https://doi.org/10.21518/2079-701x-2016-14-36-41
Pakhomova, I. G. (2013). Functional dyspepsia as a manifestation of gastrointestinal dysmotility. Medical Council, 6, 33–38.
Huberhryts, N. B., Holubova, O. A., Lukashevych, H. M., Rakhmetova, V. S. (2013). Suchasna hastroenterolohiia, 2(70), 99–103.
Palii, I. H., Zaika, S. V. (2011). Zdorovia Ukrainy, 5(258), 77.
Svintsitskyi, A. (2013). Functional Dyspepsia: Current Approaches to Diagnosis and Treatment. Lviv Clinical Bulletin, 1(1), 47–53. https://doi.org/10.25040/lkv2013.01.047
Chistik, T. (2013). Narusheniia motoriki zheludochno-kishechnogo trakta kak vazhneishii aspekt funktcionalnykh zabolevanii. Novosti meditciny i farmatcii. Gastroenterologiia. Tematicheskii nomer (446). Available at: https://www.mif-ua.com/archive/article/34897
Palii, I. H., Barannikov, K. V. (2013). Praktykuiuchyi likar, 2, 87–92.
Palii, I. H. (2013). Praktykuiuchyi likar, 3, 25–30.
Bezsheiko, V. H. (2013). Ukrainskyi medychnyi chasopys, 3(95), V-VI, 81–85.
Beliaeva, Yu. N. (2013). Biulleten medytsynskykh Ynternet-konferentsyi, 3(3), 566–568.
Tarasova, L. V., Trukhan, D. Y. (2015). Acta medica Eurasica, 4, 29–40.
Iakovlieva, L. V., Skryshevska, A. V., & Muzyka, N. Y. (2018). Analysis of the main socio-economic characteristics of ACE inhibitors and their consumption trends in Ukraine. Ukraïns’kij Bìofarmacevtičnij Žurnal, 2(55), 41–48. https://doi.org/10.24959/ubphj.18.168
Kotvitska, A. A., & Kostiuk, V. H. (2016). Farmatsevtychnyi chasopys, 2, 48–53.
Mnushko, Z. M., Karam, Akhmed, Sofronova, I. V. (2010). Ukrainskyi zhurnal klinichnoi ta laboratornoi medytsyny, 5(2), 53–57.
Nemchenko, A., & Fursa, L. (2016). The marketing research of anticancer drugs for the treatment of lung cancer. Social Pharmacy In Health Care, 2(2), 59–67. https://doi.org/10.24959/sphhcj.16.37
Morozov, A. M., Yakovlieva, L. V., Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., Dumenko, T. M., Matiashova, N. O., Adonkina, V. Yu., Chynush, I. V. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATS/DDDmetodolohiia). Kharkiv, 34.
Cheberda, A. E. (2017). Kachestvennaia klinicheskaia praktika, 1, 42–45.
Sammul, M. (Ed.). (2017). Statistical yearbook of the state agency of medicines 2017. Tartu: State Agency of Medicines.
Estonian Statistics on Medicines 2017. (2017). Available at: https://www.ravimiamet.ee/sites/default/files/ddd_2017_eng.pdf
Estonian Statistics on Medicines 2018. (2018). Available at: http://www.ravimiamet.ee/en/statistics-medicines
Ataskaita apie 2018 metais suvartotus vaistus. (2018). Available at: https://www.vvkt.lt
Statistics on medicines consumption 2018. (2019). Riga: State Agency of Medicines.
Sakshaug, S., Olsen K., Berg, Ch., Salvesen, Blix H., Storehagen, Live D., Litleskare, I. & Granum, T. (2019). Legemiddelforbruket I Norge 2014-2018. Legemiddelstatistikk 2019:1. Oslo: Folkehelseinstituttet.
Systema doslidzhennia rynku likarskykh zasobiv «Pharmexplorer» kompanii «Morion». (n.d.). Available at: http://www.pharmstandart.com.ua
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
